Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.

Guangdong Hybribio Biotech Co.,Ltd.

山东前沿医疗器械股份有限公司 manufactures medical ozone therapy devices and other medical equipment, self-described as a high-tech enterprise.

山东前沿医疗器械股份有限公司

凯普生物 is focused on the research, development, production, and sales of nucleic acid molecular diagnostic products, including molecular diagnostic reagents and related instruments. It also provides related services.

Metric
Company Name	Guangdong Hybribio Biotech Co.,Ltd.	山东前沿医疗器械股份有限公司
Symbol	300.64K
MSH ID	CN:HYBRIBIO	CN:COM:ZAMT
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Medical - Diagnostics & Research	Medical Devices
Country	HK	CN
Stage
Employee Count	2.67K
Website	hybribio.cn	zamt.com.cn
LinkedIn
Founders

Metric
Market Cap	423.02M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	150.49M
Revenue (LTM)
Revenue (NTM)
Gross Profit	78.73M
EBITDA	26.01M
Operating Income	-442.99K
Net Income	19.32M
EPS	0.03
Diluted EPS	0.03
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.68
Operating Profit Margin	0.16
EBITDA Margin	0.17
Net Profit Margin	0.18
Return on Equity	0.08
Return on Assets	0.06
Return on Capital Employed	0.07

3006

CN:HYBRIBIO

凯普生物

Last Close

6.54

25/11 07:04

Market Cap

3.08B

Beta: -

Volume Today

28.42M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	6.61
P/B Ratio	0.53
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.42
EV Multiple	7.07

Metric
Days Sales Outstanding	383.52
Days Payables Outstanding	89.15
Days Inventory Outstanding	85.49
Operating Cycle	803.71
Cash Conversion Cycle	696.89
Asset Turnover	0.36

Metric
Operating Cash Flow	45.01M
Free Cash Flow	-7.99M
Cash Flow to Debt	5.43
Operating Cash Flow/Sales	0.25
Free Cash Flow Yield	-0.05

Metric
Cash & Equivalents	105.21M
Accounts Receivable	120.15M
Inventory	13.69M
Goodwill
Debt to Capitalization	0.02
Debt to Assets	0.02
Current Ratio	4.57
Quick Ratio	7.85

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.09
SG&A to Revenue	0.02